| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K64610608 | CTRPv2 | pan-cancer | AAC | 0.0015 | 1 |
| mRNA | NVP-231 | CTRPv2 | pan-cancer | AAC | 0.0011 | 1 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | 0.002 | 1 |
| mRNA | LBW242 | CCLE | pan-cancer | AAC | -0.0015 | 1 |
| mRNA | PD 153035 | CTRPv2 | pan-cancer | AAC | 0.0012 | 1 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | 0.00099 | 1 |
| mRNA | dinaciclib | CTRPv2 | pan-cancer | AAC | 0.0012 | 1 |
| mRNA | alvocidib | CTRPv2 | pan-cancer | AAC | -0.0012 | 1 |
| mRNA | BMS-195614 | CTRPv2 | pan-cancer | AAC | 0.00092 | 1 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.00078 | 1 |